additional effect of methylene blue to empagliflozin on diabetic nephropathy

Phase 2

Conditions: Diabetic nephropathy.
Type 2 diabetes mellitus with renal complications
E11.2

Registration Number: IRCT20191228045924N7

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 50

Inclusion Criteria

Individuals diagnosed with type 2 diabetes between the ages of 25 and 65 are eligible for inclusion in the study.
Patients with a Glomerular Filtration Rate (GFR) greater than 25 and less than 90
Absence of liver insufficiency or active liver disease
Absence of active infection and sepsis.
Exclusion of professional athletes and individuals who have not engaged in intense physical exercise in the 9 days leading up to the sample collection.
Patients not currently undergoing treatment with insulin.
Patients with no history of polycystic kidney disease.
Absence of acute kidney failure due to causes other than diabetes, such as infection.
No history of cardiovascular diseases
No history of uncontrolled high blood pressure.
Absence of cancer or any other endocrine diseases.
Not having Glucose 6-phosphate dehydrogenase (G6PD) deficiency

Exclusion Criteria

Patient's non-consent for continued cooperation.
Absence of cancer or any other endocrine diseases.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in microalbuminuria. Timepoint: At time point zero (prior to drug administration), three months, and six months after drug administration. Method of measurement: laboratory test.;Enhancement in GFR (Glomerular Filtration Rate). Timepoint: At time point zero (prior to drug administration), one month, three months, and six months after drug administration. Method of measurement: Laboratory test and Calculation of the Glomerular Filtration Rate (GFR).

Secondary Outcome Measures